COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Edwin Yau, MD, PhD

Edwin Yau

Dr. Yau graduated from the University at Buffalo State University of New York School of Medicine & Biomedical Sciences in 2011. His undergraduate studies were completed at Johns Hopkins University in Baltimore, Maryland.

Selected Publications

Abdelmaksoud HE, Yau EH, Zuker M, and Sullivan JM. Development of Lead Hammerhead Ribozyme Candidates against Human Rod Opsin for Retinal Degeneration Therapy. Exp Eye Res.2009 May; 88(5): 859-879. Cited in PubMed; PMID: 19094986.

Kolniak T, Yau E, Taggart R, and Sullivan JM. Identification of Lead Candidate Ribozymes for Human Rod Opsin Therapeutics. Invest. Ophthalmol. Vis. Sci..2007 May; 48(Abstract): 1682.

Kolniak T, Yau EH, Butler MC, and Sullivan JM. Cellular Toxicity Screening of Candidate Therapeutic Ribozyme Chimeras. Invest. Ophthalmol. Vis. Sci..2008 Apr; 49(Abstract): 1699.

Kolniak TA, Butler MC, Taggart RT, Yau EH, Benz R, Fliesler SJ, and Sullivan JM. A Novel Fully Humanized RHO
adRP Mouse Model. Invest. Ophthalmol. Vis. Sci..2010 May; 51(Abstract): 4071.

Kolniak TA, Yau EH, and Sullivan JM. Modifications to Adenoviral VAI RNA as a Cytoplasmic Carrier for Post-
Transcriptional Gene Silencing Agents. Invest. Ophthalmol. Vis. Sci..2009 May; 50(Abstract): 3018.

Sullivan JM and Yau EH. Human-Directed RNA Drug Discovery - Are Animal mRNA Targets Suitable
Representatives?. Invest. Ophthalmol. Vis. Sci..2009 May; 50(Abstract): 3016.

Sullivan JM, Yau EH, Taggart RT, Butler MC, and Kolniak TA. Bottlenecks in development of retinal therapeutic posttranscriptional gene silencing agents. Vis Res.2008 Feb; 48(3): 453-469. Cited in PubMed; PMID: 17976683.